There is limited research available on the factors that affect survival in patients with non-cirrhotic hepatocellular carcinoma (HCC-NCL). Our goal was to develop and validate a nomogram and a new risk stratification system to evaluate the overall survival (OS) in patients with HCC-NCL.
Clinical informations on patients diagnosed with hepatocellular carcinoma between 2010 and 2019 were gathered using SEER*Stat 8.4.0.1, encompassing information from 17 different centers.
inclusion criteria: (1) Hepatocellular carcinoma (HCC) selected using ICD-O-3 histological codes (8170-3, 8171-3, 8172-3, 8173-3, 8174-3, 8175-3); (2) HCC patients without cirrhosis (Ishak 0-4; No to moderate fibrosis; METAVIR F0-F3; Batt-Ludwig 0-3).
A total of 15 covariates were selected for analysis in this study, namely age, marital status, gender, race, AFP, radiotherapy, chemotherapy, systemic therapy, surgery, T stage, N stage, M stage, AJCC stage, tumor size and histologic grade. All patients were staged according to AJCC 8th edition.
The patients were categorized into three groups based on the RX Summ–Surg Prim Site (1998+) field. These groups include:
(1) absence of surgery (A000);
(2) local destruction of tumor (A100-A170);
(3) liver resection or liver transplantation (A200-A750).